{
    "Trade/Device Name(s)": [
        "diaDexus PLAC\u2122 test",
        "diaDexus PLAC\u2122M test"
    ],
    "Submitter Information": "diaDexus, Inc.",
    "510(k) Number": "K050523",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NOE"
    ],
    "Summary Letter Date": "June 15, 2005",
    "Summary Letter Received Date": "April 29, 2005",
    "Submission Date": "April 28, 2005",
    "Regulation Number(s)": [
        "21 CFR 866.5600"
    ],
    "Regulation Name(s)": [
        "Low-density lipoprotein immunological test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "toxicology"
    ],
    "Analyte(s)": [
        "Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)"
    ],
    "Specimen Type(s)": [
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "Sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Quantitative determination"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent",
        "Calibrator",
        "Antibody",
        "Microwell strip"
    ],
    "Document Summary": "FDA 510(k) summary for diaDexus PLAC\u2122 enzyme immunoassay kit for quantitative measurement of Lp-PLA2 in plasma to aid in predicting coronary heart disease and ischemic stroke risk",
    "Indications for Use Summary": "Enzyme immunoassay for quantitative determination of Lp-PLA2 in human plasma, used as an aid in predicting risk for coronary heart disease and ischemic stroke associated with atherosclerosis in conjunction with clinical evaluation and patient risk assessment",
    "fda_folder": "Immunology"
}